Studies on Prn variation in the mouse model and comparison with epidemiological data

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  van Gent, Marjolein ^a   van Loo, Inge H M ^b   Heuvelman, Kees J ^a   de Neeling, Albert J ^a   Teunis, Peter ^a   Mooi, Frits R ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PERTACTIN; PERTACTIN 1; PERTACTIN 2; PERTACTIN 3; PERTUSSIS TOXIN; UNCLASSIFIED DRUG; BORDETELLA VIRULENCE FACTOR; OUTER MEMBRANE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BORDETELLA PERTUSSIS; CONTROLLED STUDY; GENE INACTIVATION; LUNG; MICROBIAL POPULATION DYNAMICS; MOUSE; NONHUMAN; PERTACTIN GENE; PROMOTER REGION; PTXP GENE; STRAIN DIFFERENCE; TRACHEA; VACCINATION; ALLELE; ANIMAL; BACTERIAL COUNT; COMPARATIVE STUDY; DISEASE MODEL; GENE SILENCING; GENETIC VARIABILITY; GENETICS; HUMAN; MICROBIOLOGY; NETHERLANDS; PATHOLOGY; PERTUSSIS; RESPIRATORY SYSTEM; TIME;

BORDETELLA PERTUSSIS; MUS;

ALLELES; ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; GENE SILENCING; GENETIC VARIATION; HUMANS; MICE; NETHERLANDS; RESPIRATORY SYSTEM; TIME FACTORS; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH;

EID: 79953033439     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018014     Document Type: Article

References (50)

1. He Q, Mertsola J, (2008) Factors contributing to pertussis resurgence. Future Microbiol 3: 329-339.
2. Berbers GA, de Greeff SC, Mooi FR, (2009) Improving pertussis vaccination. Hum Vaccin 5: 497-503.
3. Mooi FR, (2010) Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen. InfectGenetEvol 10: 36-49.
4. de Melker HE, Versteegh FG, Schellekens JF, Teunis PF, Kretzschmar M, (2006) The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J Infect 53: 106-113.
5. Halperin SA, (2007) The control of pertussis-2007 and beyond. N Engl J Med 356: 110-113.
6. Kallonen T, He Q, (2009) Bordetella pertussis strain variation and evolution postvaccination. ExpertRevVaccines 8: 863-875.
7. Hozbor D, Mooi F, Flores D, Weltman G, Bottero D, et al. (2009) Pertussis epidemiology in Argentina: trends over 2004-2007. J Infect 59: 225-231.
8. Mooi FR, van Oirschot H, Heuvelman K, van der Heide HG, Gaastra W, et al. (1998) Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. InfectImmun 66: 670-675.
9. Komatsu E, Yamaguchi F, Abe A, Weiss AA, Watanabe M, (2010) Synergic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular pertussis vaccine in the murine intranasal challenge model. Clin Vaccine Immunol 17: 807-812.
10. Bottero D, Gaillard ME, Fingermann M, Weltman G, Fernandez J, et al. (2007) Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strains. ClinVaccine Immunol 14: 1490-1498.
11. Gzyl A, Augustynowicz E, Gniadek G, Rabczenko D, Dulny G, et al. (2004) Sequence variation in pertussis S1 subunit toxin and pertussis genes in Bordetella pertussis strains used for the whole-cell pertussis vaccine produced in Poland since 1960: efficiency of the DTwP vaccine-induced immunity against currently circulating B. pertussis isolates. Vaccine 22: 2122-2128.
12. Watanabe M, Nagai M, (2002) Effect of acellular pertussis vaccine against various strains of Bordetella pertussis in a murine model of respiratory infection. J Health Science J Health Science 48: 560-564.
13. King AJ, Berbers G, van Oirschot HF, Hoogerhout P, Knipping K, et al. (2001) Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity. Microbiology 147: 2885-2895.
14. Mooi FR, van Loo IH, van Gent M, He Q, Bart MJ, et al. (2009) Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. EmergInfectDis 15: 1206-1213.
15. Bart MJ, van Gent M, van der Heide HG, Boekhorst J, Hermans P, et al. (2010) Comparative genomics of prevaccination and modern Bordetella pertussis strains. BMCGenomics 11: 627.
16. Octavia S, Maharjan RP, Sintchenko V, Stevenson G, Reeves PR, et al. (2010) Insight into evolution of Bordetella pertussis from comparative genomic analysis: evidence of vaccine-driven selection. Mol Biol Evol.
17. Leininger E, Roberts M, Kenimer JG, Charles IG, Fairweather N, et al. (1991) Pertactin, an Arg-Gly-Asp-containing Bordetella pertussis surface protein that promotes adherence of mammalian cells. Proc Natl Acad Sci U S A 88: 345-349.
18. Borisova O, Kombarova SY, Zakharova NS, van Gent M, Aleshkin VA, et al. (2007) Antigenic divergence between Bordetella pertussis clinical isolates from Moscow, Russia, and vaccine strains. ClinVaccine Immunol 14: 234-238.
19. Hallander HO, Advani A, Donnelly D, Gustafsson L, Carlsson RM, (2005) Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs. JClinMicrobiol 43: 2856-2865.
20. Yao SM, Lin YC, Chou CY, Chen YY, Hsiao MJ, et al. (2005) Antigenic divergence of Bordetella pertussis isolates in Taiwan. J Clin Microbiol 43: 5457-5461.
21. Poynten M, McIntyre PB, Mooi FR, Heuvelman KJ, Gilbert GL, (2004) Temporal trends in circulating Bordetella pertussis strains in Australia. Epidemiol Infect 132: 185-193.
22. Kodama A, Kamachi K, Horiuchi Y, Konda T, Arakawa Y, (2004) Antigenic divergence suggested by correlation between antigenic variation and pulsed-field gel electrophoresis profiles of Bordetella pertussis isolates in Japan. J Clin Microbiol 42: 5453-5457.
23. Peppler MS, Kuny S, Nevesinjac A, Rogers C, de Moissac YR, et al. (2003) Strain variation among Bordetella pertussis isolates from Quebec and Alberta provinces of Canada from 1985 to 1994. J Clin Microbiol 41: 3344-3347.
24. Weber C, Boursaux-Eude C, Coralie G, Caro V, Guiso N, (2001) Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. J Clin Microbiol 39: 4396-4403.
25. Gzyl A, Augustynowicz E, van Loo I, Slusarczyk J, (2001) Temporal nucleotide changes in pertactin and pertussis toxin genes in Bordetella pertussis strains isolated from clinical cases in Poland. Vaccine 20: 299-303.
26. Fry NK, Neal S, Harrison TG, Miller E, Matthews R, et al. (2001) Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom. InfectImmun 69: 5520-5528.
27. Cassiday P, Sanden G, Heuvelman K, Mooi F, Bisgard KM, et al. (2000) Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999. J Infect Dis 182: 1402-1408.
28. Mooi FR, He Q, van Oirschot H, Mertsola J, (1999) Variation in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland. InfectImmun 67: 3133-3134.
29. Njamkepo E, Cantinelli T, Guigon G, Guiso N, (2008) Genomic analysis and comparison of Bordetella pertussis isolates circulating in low and high vaccine coverage areas. MicrobesInfect 10: 1582-1586.
30. Mastrantonio P, Spigaglia P, van Oirschot H, van der Heide HG, Heuvelman K, et al. (1999) Antigenic variants in Bordetella pertussis strains isolated from vaccinated and unvaccinated children. Microbiology 145 (Pt 8): 2069-2075.
31. Bouchez V, Brun D, Cantinelli T, Dore G, Njamkepo E, et al. (2009) First report and detailed characterization of B. pertussis isolates not expressing Pertussis Toxin or Pertactin. Vaccine 27: 6034-6041.
32. Parkhill J, Sebaihia M, Preston A, Murphy LD, Thomson N, et al. (2003) Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. NatGenet 35: 32-40.
33. Stibitz S, Yang MS, (1991) Subcellular localization and immunological detection of proteins encoded by the vir locus of Bordetella pertussis. J Bacteriol 173: 4288-4296.
34. Stibitz S, Black W, Falkow S, (1986) The construction of a cloning vector designed for gene replacement in Bordetella pertussis. Gene 50: 133-140.
35. Schouls LM, van der Heide HG, Vauterin L, Vauterin P, Mooi FR, (2004) Multiple-locus variable-number tandem repeat analysis of Dutch Bordetella pertussis strains reveals rapid genetic changes with clonal expansion during the late 1990s. JBacteriol 186: 5496-5505.
36. Mooi FR, Hallander H, Wirsing von Konig CH, Hoet B, Guiso N, (2000) Epidemiological typing of Bordetella pertussis isolates: recommendations for a standard methodology. EurJClinMicrobiolInfectDis 19: 174-181.
37. van Loo IH, Mooi FR, (2002) Changes in the Dutch Bordetella pertussis population in the first 20 years after the introduction of whole-cell vaccines. Microbiology 148: 2011-2018.
38. Verwey WF, Thiele EH, Sage DN, Schuchardt LF, (1949) A Simplified Liquid Culture Medium for the Growth of Hemophilus Pertussis. J Bacteriol 58: 127-134.
39. Carbonetti NH, Artamonova GV, Mays RM, Worthington ZE, (2003) Pertussis toxin plays an early role in respiratory tract colonization by Bordetella pertussis. Infect Immun 71: 6358-6366.
40. Hazenbos WL, van den Berg BM, van't Wout JW, Mooi FR, van Furth R, (1994) Virulence factors determine attachment and ingestion of nonopsonized and opsonized Bordetella pertussis by human monocytes. Infect Immun 62: 4818-4824.
41. McGuirk P, Mills KH, (2000) Direct anti-inflammatory effect of a bacterial virulence factor: IL-10-dependent suppression of IL-12 production by filamentous hemagglutinin from Bordetella pertussis. Eur J Immunol 30: 415-422.
42. Nicholson TL, Brockmeier SL, Loving CL, (2009) Contribution of Bordetella bronchiseptica filamentous hemagglutinin and pertactin to respiratory disease in swine. Infect Immun 77: 2136-2146.
43. Inatsuka CS, Xu Q, Vujkovic-Cvijin I, Wong S, Stibitz S, et al. (2010) Pertactin is required for Bordetella species to resist neutrophil-mediated clearance. Infect Immun 78: 2901-2909.
44. Roberts M, Fairweather NF, Leininger E, Pickard D, Hewlett EL, et al. (1991) Construction and characterization of Bordetella pertussis mutants lacking the vir-regulated P.69 outer membrane protein. Mol Microbiol 5: 1393-1404.
45. Stefanelli P, Fazio C, Fedele G, Spensieri F, Ausiello CM, et al. (2009) A natural pertactin deficient strain of Bordetella pertussis shows improved entry in human monocyte-derived dendritic cells. New Microbiol 32: 159-166.
46. Khelef N, Bachelet CM, Vargaftig BB, Guiso N, (1994) Characterization of murine lung inflammation after infection with parental Bordetella pertussis and mutants deficient in adhesins or toxins. Infect Immun 62: 2893-2900.
47. Leininger E, Ewanowich CA, Bhargava A, Peppler MS, Kenimer JG, et al. (1992) Comparative roles of the Arg-Gly-Asp sequence present in the Bordetella pertussis adhesins pertactin and filamentous hemagglutinin. Infect Immun 60: 2380-2385.
48. Packard ER, Parton R, Coote JG, Fry NK, (2004) Sequence variation and conservation in virulence-related genes of Bordetella pertussis isolates from the UK. JMedMicrobiol 53: 355-365.
49. Elomaa A, Advani A, Donnelly D, Antila M, Mertsola J, et al. (2005) Strain variation among Bordetella pertussis isolates in finland, where the whole-cell pertussis vaccine has been used for 50 years. J Clin Microbiol 43: 3681-3687.
50. Advani A, Donnelly D, Gustafsson L, Hallander HO, (2007) Changes of the Swedish Bordetella pertussis population in incidence peaks during an acellular pertussis vaccine period between 1997 and 2004. APMIS 115: 299-310.